[go: up one dir, main page]

MX2015010174A - Herramientas de diagnostico para predecir la presentacion de preeclampsia. - Google Patents

Herramientas de diagnostico para predecir la presentacion de preeclampsia.

Info

Publication number
MX2015010174A
MX2015010174A MX2015010174A MX2015010174A MX2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A MX 2015010174 A MX2015010174 A MX 2015010174A
Authority
MX
Mexico
Prior art keywords
preeclampsia
diagnostic tools
predict onset
onset
predict
Prior art date
Application number
MX2015010174A
Other languages
English (en)
Inventor
Mark K Santillan
Justin L Grobe
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2015010174A publication Critical patent/MX2015010174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C12Y304/11003—Cystinyl aminopeptidase (3.4.11.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Se describen ensayos, kits, métodos, y dispositivos para diagnosticar o predecir la probabilidad de ocurrencia de preeclampsia en una paciente.
MX2015010174A 2013-02-08 2014-02-10 Herramientas de diagnostico para predecir la presentacion de preeclampsia. MX2015010174A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361762830P 2013-02-08 2013-02-08
US201361762831P 2013-02-08 2013-02-08
US201361906074P 2013-11-19 2013-11-19
PCT/US2014/015627 WO2014124392A1 (en) 2013-02-08 2014-02-10 Diagnostic tools to predict onset of preeclampsia

Publications (1)

Publication Number Publication Date
MX2015010174A true MX2015010174A (es) 2016-03-31

Family

ID=51300184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010174A MX2015010174A (es) 2013-02-08 2014-02-10 Herramientas de diagnostico para predecir la presentacion de preeclampsia.

Country Status (8)

Country Link
US (3) US9937182B2 (es)
EP (1) EP2954324B1 (es)
JP (1) JP2016507753A (es)
KR (1) KR20150119009A (es)
CN (1) CN105308456A (es)
CA (1) CA2900366A1 (es)
MX (1) MX2015010174A (es)
WO (2) WO2014124392A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357469B2 (en) * 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
JP6885608B2 (ja) * 2015-07-15 2021-06-16 ジェストビジョン・インコーポレイテッド ミスフォールドタンパク質を検出するためのデバイスおよびその使用方法
US10654919B2 (en) 2015-10-05 2020-05-19 The Feinstein Institutes For Medical Research Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies
CA2929810A1 (en) * 2016-04-29 2017-10-29 University Of Iowa Research Foundation Improved early prediction of preeclampsia
WO2018076134A1 (en) * 2016-10-24 2018-05-03 Ldx Prognostics Limited Co. Methods and kits for providing a preeclampsia assessment and prognosing preterm birth
US20200124612A1 (en) * 2017-04-11 2020-04-23 University Of Iowa Research Foundation Detection of predictors of preeclampsia
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
CN108152495A (zh) * 2017-12-27 2018-06-12 江苏华鸣生物科技有限公司 一种检测酪氨酸的胶体金试纸
WO2020169799A1 (en) * 2019-02-21 2020-08-27 B.R.A.H.M.S Gmbh Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
US10844435B1 (en) 2020-07-17 2020-11-24 Par Pharmaceutical, Inc. Method to treat hypotension using vasopressin in certain genotypes
CN112126683A (zh) * 2020-08-31 2020-12-25 中山大学 用于迟发型子痫前期诊断的标志物
WO2023076257A1 (en) * 2021-10-25 2023-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for diagnosing leptominingeal metastasis
CN120028553B (zh) * 2025-04-23 2025-08-22 北京水木济衡生物技术有限公司 一种多项目复合产前筛查质控品及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733787A (en) 1996-06-17 1998-03-31 Bayer Corporation Method for the detection of creatinine
US6210971B1 (en) 1999-01-25 2001-04-03 Bayer Corporation Assay for the detection of creatinine
US20030121067A1 (en) 2001-09-24 2003-06-26 Brennan Thomas J. V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto
US7723124B2 (en) * 2004-02-09 2010-05-25 Rapid Pathogen Screening, Inc. Method for the rapid diagnosis of targets in human body fluids
EP1742932A1 (en) * 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
GB0600916D0 (en) * 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
DE102006034142A1 (de) * 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
KR20100016445A (ko) * 2007-04-11 2010-02-12 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
US20110251094A1 (en) * 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
EP2706041B1 (en) * 2010-05-14 2018-10-03 Beth Israel Deaconess Medical Center Extracorporeal devices and methods of treating complications of pregnancy
RU2013102112A (ru) * 2010-06-18 2014-07-27 Сезанн С.А.С. Маркеры для прогнозирования и оценки риска развития обусловленных беременностью гипертензии и преэклампсии
AU2011340630B2 (en) * 2010-12-06 2017-01-19 Mycartis Nv Biomarkers and parameters for hypertensive disorders of pregnancy

Also Published As

Publication number Publication date
US20180228806A1 (en) 2018-08-16
EP2954324B1 (en) 2019-07-31
EP2954324A1 (en) 2015-12-16
US9937182B2 (en) 2018-04-10
WO2014124396A1 (en) 2014-08-14
WO2014124392A1 (en) 2014-08-14
US20150374698A1 (en) 2015-12-31
US20150377876A1 (en) 2015-12-31
CA2900366A1 (en) 2014-08-14
KR20150119009A (ko) 2015-10-23
JP2016507753A (ja) 2016-03-10
EP2954324A4 (en) 2017-01-04
CN105308456A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
MA40325A (fr) Procédés et compositions pour diagnostiquer, pronostiquer et confirmer une pré-éclampsie.
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
GB201516569D0 (en) Methods, compositions, and kits for nucleic acid analysis
EP3064940A4 (en) Salivary biomarker for cancer, method and device for assaying same, and method for determining salivary biomarker for cancer
WO2015009734A3 (en) Assays for antimicrobial activity and applications thereof
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
HK1218576A1 (zh) 结核病生物标志物及其用途
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
FI3511422T3 (fi) Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
GB201413229D0 (en) Assay devices, methods for carrying out assays, assay kits and method for manufacturing assay devices
EP3036712A4 (en) Methods for predicting prognosis
GB2532684A (en) Wellbore operations involving computational methods that produce sag profiles
WO2016023991A8 (de) Verfahren zur mikrobiom-analyse
MX2015015602A (es) Metodo para programar un episodio de diagnostico.
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
EP2820414A4 (en) METHOD AND KITS FOR DETECTING AND DIAGNOSIS OF NEUROTRAUMATA
EP2972344A4 (en) Methods and compositions for diagnosing preeclampsia
IL274477A (en) Biomarker assays for use in autism surveillance
WO2014072832A3 (en) Biomarkers for cervical cancer
IL240129B (en) Methods and kits for determining the risk of getting extrapyramidal symptoms (eps) as a result of treatment with antipsychotics
WO2014160237A3 (en) Methods of prognosing preeclampsia
PL3283889T3 (pl) Sposób i test do diagnozowania gwałtownie postępującego zapalenia kłębuszków nerkowych u osobnika
MY156871A (en) Detection methods for oil palm shell alleles